Afleveringen
-
Tune into a brand new episode of the Market Access Podcast to listen to an intriguing conversation about the Italian healthcare system with Giacomo Matteo Bruno and Dr Stefan Walzer. Together they explore the balance between innovation, sustainability, and patient access in the heart of Europe. Discover the evolution, challenges, and future of healthcare in Italy, from the foundational principles laid down in 1978 to the dynamic, ever-evolving landscape of today.
Giacomo shares his insights on how to navigate the crucial role of health economics in drug pathways as well as giving a birds-eye perspective over the healthcare system in Italy today and the challenges that comes with an aging population and rising chronic diseases. Giacomo presents a vision for embracing innovation while maintaining the system’s integrity.
If you are searching for deeper knowledge about the Italian healthcare system and learn about strategies on how to enter the Italian market, this episode is for you. Learn about the regional nuances that make Italy unique, the steps for drug reimbursement, and the importance of targeted therapies in personalized medicine. Giacomo also sheds light on the pioneering electronic dossier system introduced by IFA, streamlining the approval process and setting a new standard in healthcare innovation.
Whether you're a healthcare professional, a pharmaceutical company, or just intrigued by the global healthcare landscape, this conversation offers valuable lessons and strategies for success in one of the world's most revered healthcare systems.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
#HealthcareInnovation #MarketAccess #Italy #ItalianHealthcare #PharmaceuticalIndustry #marketaccesspodcast #marketaccess
-
In this captivating episode of MAP, the Market Access Podcast, we welcome Aymeric Chaupin, a seasoned expert in pricing and market access. Aymeric's unique perspective, shaped by his deep understanding of both the American and European healthcare systems, sheds light on the complexities of healthcare reimbursement pathways in the US and their impact on the delivery of health services.
Join us as Aymeric unveils the challenges and opportunities within the US healthcare market. He emphasizes the importance of coding and understanding reimbursement pathways for effective market access and explores the broader implications for patient care and the healthcare system as a whole.
This episode is a treasure trove of insights for startups and companies looking to navigate the US healthcare landscape. Aymeric shares practical advice on entering the market, from partnering with pharmaceutical giants to engaging with the FDA early in the clinical trial process. He stresses the necessity of having a clear strategy and representation in the US to negotiate coverage and formulary placement, ensuring commercial success in this pivotal market.
Despite the hurdles, the US remains a key player in the global pharmaceutical and medical device industry, accounting for a significant portion of global revenue.
Tune in for an enlightening discussion that navigates the intricacies of the US healthcare system, providing valuable lessons and strategies for companies aspiring to make their mark in this challenging yet rewarding market.
#HealthcareInnovation #MarketAccess #US #USHealthcareSystem #PharmaceuticalIndustry #MedicalDevices #HealthcareReform #marketaccess #marketaccesspodcast
-
Zijn er afleveringen die ontbreken?
-
Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of networking, mentorship, and the essential skills for success. This episode is a must-listen for professionals looking to navigate the complex world of market access and leverage opportunities in the pharmaceutical field. Tune in to unlock your career potential with expert advice from a seasoned market access professional. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP PodcastsMAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de#Medtech #MarketAccess #Canada #HealthcareSystem #marketaccess #marketaccesspodcast #medtech
-
In this essential episode of the Market Access Podcast, we're diving deep into the critical aspects of commercializing healthcare innovations in the US market. Whether you're in medtech, pharma, biotech, or health tech, understanding the US healthcare landscape is key to your product's success. Join us as Dr. Stefan Walzer and Paul-Lukas Hoffschmidt, CEO of Alpha Sophia (www.alphasophia.com), share their wealth of knowledge on effective strategies for navigating this complex terrain.
Key Topics Covered:
Understanding US Market Access: An overview of the unique challenges and opportunities in the US healthcare system for new entrants.Role of Healthcare Professionals: Insight into how healthcare professionals influence market access and product uptake.Data-Driven Strategies: The importance of leveraging data in targeting and positioning your product effectively.Commercialization Pathways: Expert advice on navigating regulatory, reimbursement, and distribution challenges.Case Studies: Real-world examples of successful market entry and the lessons learned.Future Trends: Predictions on how the US market access landscape may evolve and what it means for healthcare innovators.Why You Should Listen:
Gain Expert Insights: Learn from leading experts with firsthand experience in the US healthcare market.Strategic Advice: Receive actionable advice on overcoming the hurdles to market entry and expansion.Stay Ahead: Understand the latest trends and how they impact market access strategies.This episode is indispensable for CEOs, entrepreneurs, market access professionals, and anyone involved in the commercialization of healthcare innovations looking to penetrate or expand their presence in the US market.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
#Medtech #MarketAccess #US #HealthcareSystem #MarketAccessPodcast
-
Join us for a fascinating dive into the complexities of French market access with our latest episode of the Map Podcast. Dr. Stefan Walzer, health economist and founder of Mars Market Access & Pricing Strategy, engages with Dr. Benoit Salaun, a seasoned expert in French healthcare reimbursement.
They unravel:
The nuances of the French healthcare systemThe essentials of medical device reimbursementThe importance of demonstrating efficacy, safety, and affordabilityThe role of clinical evidence and the adaptability of international data to French contextsThe strategic considerations for medtech companies entering the French marketWhether you’re a healthcare professional, a medtech innovator, or a market access strategist, this episode is packed with insights on how to ensure your medical device not only enters the French market but also achieves the price it deserves.
Tune in to gain expert knowledge on creating a successful roadmap for market access in France, and discover if the "French way" aligns with your company's goals.
🎧 Listen now and elevate your market access strategy!
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
#Medtech #MarketAccess #HealthcareInnovation #FrenchHealthcareSystem #marketaccess #marketaccesspodcast
-
In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71, which allows an early paid access.
Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.
In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
-
Are you intrigued by the pulsing heart of Spain’s healthcare sector, or are you considering navigating the vibrant market of medical devices in Spain? Dive into our latest Market Access podcast episode where we unravel the complexities and dynamism of Spain’s medical landscape. 🇪🇸
Join us as Sergio Gil, a seasoned veteran with over three decades in the medical device industry, shares his invaluable insights. From understanding Spain's unique regional healthcare powers to decoding the reimbursement conundrums, Sergio illuminates the path to successful market entry and what makes Spain not just culturally, but commercially captivating.
Here’s a sneak peek at what you’ll discover:
🔹 The striking differences between the pharmaceutical and medical device sectors in Spain.
🔹 An insider’s guide to Spain’s decentralized healthcare approach and how it impacts market access.
🔹 Key strategies for companies aiming to penetrate the Spanish market – straight from the expert.
🔹 The burgeoning world of digital health in Spain and the emerging trends to watch out for.
Whether you're a startup eyeing Spain for your next big launch or a seasoned player looking to deepen your market footprint, this episode is packed with strategic gold.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: map-market-access.captivate.fm
MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: marketaccess-pricingstrategy.de
#MedicalDevices #Healthcare #MarketAccess #Spain #Podcast #DigitalHealth #Innovation #BusinessStrategy
-
We are looking at Israel a lot recently, but did you know how innovative this rather small country is in terms of healthcare?
Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time, Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?
Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #israel
-
We are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff.
Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving multiple stakeholders like health insurance companies.
🔍 Key Highlights:
- Ron's path from founding his company in 1985, which has since assisted over 900 entities, including governments, in understanding medical technology markets.
- Challenges faced by startups in healthcare, often led by technical experts who struggle with the language and complexities of reimbursement processes.
- The criticality of startups understanding both the payer perspectives and the changing requirements of reimbursement systems across Europe.
- Ron's advice to startups: comprehensively understand the reimbursement system of your target market and assess if your product is likely to be reimbursable.
This episode is a must-listen for anyone in the healthcare industry, particularly startups navigating the daunting world of reimbursement. Expect to gain a thorough understanding of how to strategically plan for reimbursement, the importance of being updated with current regulations, and how to choose the right market for your product.
🌟 Tune in for a blend of expert insights, practical advice, and a glimpse into the future of healthcare reimbursement strategies. For more information on early reimbursement planning utilizing artificial intelligence, visit max-insights.com.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: marketaccess-pricingstrategy.de
#HealthcareReimbursement #StartupChallenges #MedicalTechnology #Podcast #HealthcareInnovation“
-
🎧 Excited to share our CEO, Dr. Stefan Walzer's newest Market Access podcast episode that's nothing short of a masterclass for healthcare startups venturing into the European market!
In this engaging episode, Dr. Walzer sits down with Dr. Thomas Kerscher and Mark Anken, both titans in the healthcare and pharmaceutical sectors with over two decades of experience. Currently at the helm of advantage, they're shaping the future of startups in this complex field. 🌍
Key Highlights:
1️⃣ Tailored Strategies: The critical need for startups to tailor their strategies based on product type and the unique healthcare landscapes of European countries.
2️⃣ Realistic Approach: The importance of balancing optimism with realism, especially when pitching to well-informed investors.
3️⃣ Scaling Up: The power of starting small, akin to Airbnb's model, then scaling up based on market feedback and minimal business model alterations.
4️⃣ Innovation vs. Reimbursement: Understanding the delicate balance between being innovative and navigating the reimbursement strategies crucial for startup viability.
💡 The duo shares invaluable insights on the significance of understanding your target customer, the nuances of entering varied European markets, and the complexities startups face in aligning their business models with healthcare policies. They stress the importance of innovation, not just for product differentiation, but as a tool to address cost pressures in healthcare systems.
📈 For those in healthcare startups, this episode is a goldmine of advice on developing effective business plans, understanding investor expectations, and the imperative of global market awareness.
Join us in exploring these vital topics, and gain a wealth of knowledge to propel your healthcare startup to new heights. Don't miss out on this incredible episode for a roadmap to success in the challenging yet rewarding realm of healthcare entrepreneurship.
#HealthcareStartups #MarketAccess #Podcast #Innovation #BusinessStrategy #HealthcareInvestment #EuropeanMarket #DrStefanWalzer
👉 Tune in to the full episode for a deep dive into these groundbreaking insights! 🎙️👇
-
🎙️ Exciting Podcast Episode Is Here! 🎙️
In this episode of our podcast series, I'm excited to share that Stefan Walzer, a seasoned reimbursement expert, hosts the incredibly talented Amelie Moser, a business consultant with two decades of unparalleled expertise in market access!
🎯 What's Happening?
Immerse yourself in the fascinating world of digital health and see how it sharply contrasts with traditional drug landscapes.
Grasp the challenges of moving global product strategies into local implementations, all through the lens of Aurelies experience.
Navigate the crucial role of ecosystem mapping, and learn why it's important to engage all stakeholders.
💡 Key Takeaways:
Experience the dynamic nature of strategy adaptation — it's an evolving process, not just a set document!
Join in on an enlightening discussion about the mindset shift crucial for companies making the leap from global to local viewpoints.
Gain perspective on balancing qualitative vs. quantitative data for local market achievement.
Uncover the unexplored complexities of digital health solutions and the challenges they pose.
✨ Special Mention: Dive deep with Aurelie as she discusses her founding venture, BAMBOOSTER, and how she plays a crucial role in connecting top pharma giants with startups in the digital health and AI sectors.
If the evolving landscape of healthcare piques your curiosity as much as it does mine, you won't want to miss this episode. Listen now for this enlightening conversation! 🚀
🔗 Find the 3C Business Model Canvas here.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#DigitalHealth #MarketAccess #Podcast #HealthcareInnovation #LocalVsGlobal #StrategiesForSuccess
-
Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!
🚀 Dive Deep into the Core of Pharmaceutical Reforms!
Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀
🌎 Explore the Global Impact!
Navigate through their insightful discussion on how these reforms potentially sculpt Germany’s presence on the global stage, especially in the orphan drugs market, and assess Germany's unique positioning in evaluating them! 🌎
💡 Illuminating the Opaqueness of Drug Pricing!
Embark on a journey through the complexities and pragmatic implications of drug pricing, dissecting the nuances of arbitration boards, pricing mechanisms, and the often intricate physician prescription behaviors amidst the recent reforms. 💡
🤔 Facing the Challenges Head-On!
Explore the potential disconnect between pricing strategies and actual prescription practices, as our experts shed light on the vital need for enhancing transparency and communication with physicians regarding pricing negotiations and adjustments. 🤔
👥 Join Matthias and Stefan as they scrutinize the germane issues of drug pricing, contemplate future adjustments within the system, and ponder upon the possible shifts influenced by the upcoming national elections and continual changes within the healthcare landscape! 👥
🎧 Tune in to immerse yourself in a conversation that not only explores the multidimensional aspects of the healthcare and pharmaceutical reimbursement system but also poses potent questions regarding its future amidst regulatory and structural shifts! 🎧
A journey through the dynamics of pharmaceutical pricing and reforms awaits you, amplifying both economic and patient care perspectives amidst the shifting tides of the healthcare system in Germany! Don’t miss it! 🚀🚀
-
Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“.
Dr. Heiner Sandmeier has been part of the drug evaluation committee advising the Swiss decision makers for over a century and opens his insights and secrets to all listeners.
Some of the topics Dr. Sandmeier and reimbursement veteran Dr. Stefan Walzer discuss are as follows:
What are the main drivers for a positive decision in Switzerland?Who is involved in the decision process?What are the challenges as well as possible solutions for the main issues?What are the differences to other countries in Europe?And last but not least: Why should you still consider to enter the Swiss market with an innovative pharmaceutical product?
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #pricingstrategy #negotiations #pricing #pharmaceuticals #switzerland #innovation #reimbursement
-
Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:
- What are the differences between Clinical Development and Medical Affairs?
- When should a company start telling their medical story about a new product?
- What are the differences between drugs and vaccinations from a medical affairs’ perspective?
- And how should market access and medical affairs ideally work together?
Market access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access continued their come together in Boston in May 2023 in this epic podcast episode.
Don’t miss this amazing conversation.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #medicalaffairs #pricingstrategy #negotiations
#pricing #medtech #pharmaceuticals #usa #innovation #vaccination
-
🎧 Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems...
💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisation! In this MAP podcast episode, health care system veteran Dr. Stefan Walzer and Dr. Peter Indra are discussing the current state of digital health in Switzerland, possible improvements and the inspiring example of Estonia.
What are we talking about, when we address the topic of digitalisation and e-health?
Data + AI, which is dealing with the dataInfrastructure like electronic patient record and vaccination registriesProcessesDon't miss this inspiring conversation with spill-overs for all countries around the world.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #digitization #digitalhealth #funding #ehealth #healthcare #digitalisation #healthservices #switzerland
-
Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in danger of failing.
Already in the very early stages of the development of pharmaceuticals or med tech products, companies need to think about the following key points:
Will patients need and want the new product?
Will physicians prescribe it?
Will payers pay for it?
And thus they should come up with a convincing value story towards all stakeholders as only if they could convince all of these, investors will see the potential return of investment! But ultimately, all of that needs to be communicated… The reimbursement veteran Dr. Stefan Walzer these and more aspects around (global and local) communication with the communication expert Dr. Arne Näveke.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #medtech #pharmaceuticals #communications #funding #medicaldevices #germany
-
Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-committee of the German federal Committee (G-BA) the so-called evaluation committee. But how does that body come to a conclusion and what do they really assess. How does price setting work in such an environment.
The reimbursement veteran Dr. Stefan Walzer discussed all of these questions and many more secrets with the Head of the arbitration board of the before-mentioned evaluation committee, Prof. Jürgen Wasem.
✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations
#pricing #medtech #diagnostics #arbitrationboard #funding #medicaldevices #germany
-
Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?
In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with - clinical development, regulatory and payers.
✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #innovation #pricing #drugs #medtech #livescience #strategy
-
In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs - are there any relationships?
The #marketaccess veterans Dr. Stefan Walzer and Dr. Jamie Cross are discussing the principles as well as some very specific details.
✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations
#pricing #drugs #medtech #usa #fda
-
The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works.
The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore.
With Medicare the government directly funds pharmaceuticals for 65+ years old population.
With Medicaid the government fund low income and other vulnerable populations.
Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease.
Revenues in the US will decline, and it will be interesting to see, what that will mean economically and in terms of availability of pharmaceuticals for the US and the global market?
Please enjoy the discussion of market access veterans Dr. Stefan Walzer and Anita Burell MBA on this major change in the major market for pharmaceuticals.
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations
#pricing #drugs #medtech #usa #inflationreductionact #inflation #ira
- Laat meer zien
